secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2022-06-21T23:59:59+00:00
Accession:  0001564590-22-023674
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics stockholders elect three Class II directors and ratify auditor at 2022 annual meeting
--------------------------------------------------------------------------------

- Martin Babler elected with 27,034,110 votes for; 54,875 withheld; 1,215,046 broker non-votes.
- Julian Baker elected with 25,635,979 votes for; 1,453,006 withheld; 1,215,046 broker non-votes.
- Victor Sandor elected with 26,057,360 votes for; 1,031,625 withheld; 1,215,046 broker non-votes.
- Ernst & Young ratified as independent auditor for FY2022: 28,293,151 for, 5,385 against, 5,495 abstain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000156459022023674/0001564590-22-023674-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000156459022023674/prld-8k_20220617.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-023674

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer